12,372 trials
Congenital Bleeding Disorder · Haemophilia A
Primary: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) ≥0.6 Bethesda Units — 0; 0 Participants
Spondyloarthritis
Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 12.5; 25.4; 30.6 Percentage of participants — p=0.017
Urinary Incontinence
Primary: Change From Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes — -1.30; -1.30; -1.34 urinary incontinence episodes per day — p=0.9949
External Cephalic Version
Primary: Mean Pain Score Experienced During Version — 5.486; 5.433 score on a scale — p=0.943
Type 1 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.02; -0.39; -0.37 Percentage of A1C — p=< 0.001
Prostate Cancer Non-Metastatic · Castration-Resistant
Primary: Metastasis-Free Survival — 40.37; 18.43 months — p=<0.000001
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
HER2-positive Carcinoma of Breast
Primary: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless…
Psoriasis Vulgaris
Primary: Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8 — 121; 67; 4 Count…
Osteoarthritis of the Knee
Primary: Total Number of Treatment Emergent Adverse Events (TEAEs) in Patients With Symptomatic Osteoarthritis (OA) of the Knee Who Received Two Doses of 32 mg FX006 — 336 TEAEs
Cystic Fibrosis
Primary: Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse…
Chagas Disease
Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects
Advanced Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib — 11.9; 9.1 Months
Bacterial Conjunctivitis
Primary: Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 5 — 111; 0; 95 Participants — p=0.127
Breast Cancer
Primary: Disease Free Survival (DFS) Events — 105; 120 Participants